Considerations for pharmacologic management of rheumatoid arthritis in the COVID-19 era: a narrative review

R Venkat, ZS Wallace, JA Sparks - Current Rheumatology Reports, 2023 - Springer
Abstract Purpose of Review To review the impact of disease-modifying antirheumatic drugs
(DMARDs) on COVID-19 severity and vaccine immunogenicity and to discuss COVID-19 …

Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the US National …

N Singh, V Madhira, C Hu, AL Olex, T Bergquist… - Seminars in Arthritis and …, 2023 - Elsevier
Objective To assess whether rituximab (RTX) is associated with worse COVID-19 outcomes
among patients with rheumatoid arthritis (RA). Methods We used the National COVID Cohort …

Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic

EG Favalli, G Maioli, M Biggioggero… - Expert Review of …, 2021 - Taylor & Francis
ABSTRACT Introduction: Coronavirus disease 2019 (COVID-19) pandemic raises a great
challenge in the management of patients with rheumatoid arthritis (RA), which are generally …

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a …

A Abhishek, N Peckham, C Pade… - The Lancet …, 2024 - thelancet.com
Background Methotrexate is the first-line treatment for immune-mediated inflammatory
diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of …

Managing rheumatoid arthritis during COVID-19

R Roongta, A Ghosh - Clinical rheumatology, 2020 - Springer
The outbreak of coronavirus in the world has led to an uncertainty about treatment of
patients with autoimmune disorders because of their weakened immune system coupled …

Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma

P Mehta, E Sanchez, E Moraitis, N Longley… - The Lancet …, 2021 - thelancet.com
With the COVID-19 pandemic continuing unabated and the advent of the influenza season,
public health authorities have emphasised that influenza vaccina tion is of paramount …

[HTML][HTML] Outcomes of COVID-19 in inflammatory rheumatic diseases: a retrospective cohort study

TS Alhowaish, MS Alhamadh, AY Alhabeeb… - Cureus, 2022 - ncbi.nlm.nih.gov
Background Similar to coronavirus disease 2019 (COVID-19), the pathogenesis of
inflammatory rheumatic diseases includes cytokines dysregulation and increased …

COVID-19 vaccination and antirheumatic therapy

J Arnold, K Winthrop, P Emery - Rheumatology, 2021 - academic.oup.com
Abstract The coronavirus disease 2019 (COVID-19) vaccination will be the largest
vaccination programme in the history of the NHS. Patients on immunosuppressive therapy …

Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study …

M Auroux, B Laurent, B Coste, E Massy, A Mercier… - Joint Bone Spine, 2022 - Elsevier
Introduction Vaccination is considered as a cornerstone of the management of COVID-19
pandemic. However, while vaccines provide a robust protection in immunocompetent …

Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial

CSR Araujo, AC Medeiros-Ribeiro… - Annals of the …, 2022 - ard.bmj.com
Objective To evaluate the effect on immunogenicity and safety of 2-week methotrexate
(MTX) discontinuation after each dose of the Sinovac-CoronaVac vaccine versus MTX …